Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

LIF and multiple sclerosis: One protein with two healing properties.

Metcalfe SM.

Mult Scler Relat Disord. 2018 Feb;20:223-227. doi: 10.1016/j.msard.2018.01.018. Epub 2018 Jan 31. No abstract available.

PMID:
29448112
2.

Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy.

Metcalfe SM, Bickerton S, Fahmy T.

Curr Pharm Des. 2017;23(5):776-783. doi: 10.2174/1381612822666161206141744.

3.

Stem cell therapy versus T lymphocytes: friend or foe?

Metcalfe SM.

Stem Cells. 2015 Feb;33(2):622-5. doi: 10.1002/stem.1863. No abstract available.

4.

Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.

Zhao JW, Dyson SC, Kriegel C, Tyers P, He X, Fahmy TM, Metcalfe SM, Barker RA.

Dis Model Mech. 2014 Oct;7(10):1193-203. doi: 10.1242/dmm.015859. Epub 2014 Aug 1.

5.

Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice.

Dong H, Fahmy TM, Metcalfe SM, Morton SL, Dong X, Inverardi L, Adams DB, Gao W, Wang H.

PLoS One. 2012;7(12):e50265. doi: 10.1371/journal.pone.0050265. Epub 2012 Dec 5.

6.

Targeted nanotherapy for induction of therapeutic immune responses.

Metcalfe SM, Fahmy TM.

Trends Mol Med. 2012 Feb;18(2):72-80. doi: 10.1016/j.molmed.2011.11.002. Epub 2011 Dec 14.

PMID:
22172276
7.

Multiple sclerosis: One protein, two healing properties.

Metcalfe SM.

Nature. 2011 Sep 14;477(7364):287-8. doi: 10.1038/477287a. No abstract available.

PMID:
21921909
8.

LIF in the regulation of T-cell fate and as a potential therapeutic.

Metcalfe SM.

Genes Immun. 2011 Apr;12(3):157-68. doi: 10.1038/gene.2011.9. Epub 2011 Mar 3. Review.

PMID:
21368774
9.

A LIF/Nanog axis is revealed in T lymphocytes that lack MARCH-7, a RINGv E3 ligase that regulates the LIF-receptor.

Thompson LH, Whiston RA, Rakhimov Y, Taccioli C, Liu CG, Croce C, Metcalfe SM.

Cell Cycle. 2010 Oct 15;9(20):4213-21. Epub 2010 Oct 4.

10.

The E3 ligase axotrophin/MARCH-7: protein expression profiling of human tissues reveals links to adult stem cells.

Szigyarto CA, Sibbons P, Williams G, Uhlen M, Metcalfe SM.

J Histochem Cytochem. 2010 Apr;58(4):301-8. doi: 10.1369/jhc.2009.954420. Epub 2009 Nov 9.

11.

Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6.

Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB, Metcalfe SM.

Cell Cycle. 2009 May 1;8(9):1444-50. Epub 2009 May 4.

12.

In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFbeta, but has no immediate effect on Foxp3.

Muthukumarana PA, Zheng XX, Rosengard BR, Strom TB, Metcalfe SM.

Transpl Int. 2008 Jun;21(6):593-7. doi: 10.1111/j.1432-2277.2008.00654.x. Epub 2008 Feb 16.

13.

Regulatory transplantation tolerance and "stemness": evidence that Foxp3 may play a regulatory role in SOCS-3 gene transcription.

Muthukumarana P, Chae WJ, Maher S, Rosengard BR, Bothwell AL, Metcalfe SM.

Transplantation. 2007 Jul 15;84(1 Suppl):S6-11.

PMID:
17632414
14.

Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance.

Muthukumarana PA, Lyons GE, Miura Y, Thompson LH, Watson T, Green CJ, Shurey S, Hess AD, Rosengard BR, Metcalfe SM.

Int Immunopharmacol. 2006 Dec 20;6(13-14):1993-2001. Epub 2006 Oct 17.

PMID:
17161353
15.

Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance.

Metcalfe SM.

Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1687-94. Review.

16.

Introduction: immunoregulation: harnessing T cell biology for therapeutic benefit.

Metcalfe SM, Calne RY, Cobbold SP.

Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1641-3. No abstract available.

17.

Leukemia inhibitory factor is linked to regulatory transplantation tolerance.

Metcalfe SM, Watson TJ, Shurey S, Adams E, Green CJ.

Transplantation. 2005 Mar 27;79(6):726-30.

PMID:
15785381
18.

Leukaemia inhibitory factor (LIF) is functionally linked to axotrophin and both LIF and axotrophin are linked to regulatory immune tolerance.

Metcalfe SM, Muthukumarana PA, Thompson HL, Haendel MA, Lyons GE.

FEBS Lett. 2005 Jan 31;579(3):609-14.

19.

Transplantation tolerance: gene expression profiles comparing allotolerance vs. allorejection.

Metcalfe SM, De S Muthukumarana PA.

Int Immunopharmacol. 2005 Jan;5(1):33-9.

PMID:
15589457
20.

Genetic modulators of interleukin 1 activity influence the development of chronic rejection in human thoracic allografts.

Vamvakopoulos JE, Taylor CJ, Green C, McNeil K, Metcalfe SM.

Transplant Proc. 2001 Feb-Mar;33(1-2):1563-4. No abstract available.

PMID:
11267421
21.
22.

STAT 6 up-regulation by FK506 in the presence of interleukin-4.

Moffatt SD, Cockman M, Metcalfe SM.

Transplantation. 2000 Apr 15;69(7):1521-3.

PMID:
10798785
23.

Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies.

Moffatt SD, McAlister V, Calne RY, Metcalfe SM.

Transplant Proc. 1999 Nov;31(7):2754. No abstract available.

PMID:
10578277
24.

FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies.

Moffatt SD, Metcalfe SM.

Transplant Proc. 1999 Nov;31(7):2740. No abstract available.

PMID:
10578271
25.

Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine.

Hughes JR, Hughes VF, Trull AK, Metcalfe SM.

Transplantation. 1999 Aug 27;68(4):583-6.

PMID:
10480422
26.

Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model.

Moffatt SD, McAlister V, Calne RY, Metcalfe SM.

Transplantation. 1999 May 15;67(9):1205-8.

PMID:
10342309
27.

Thymic-independent peripheral tolerance.

Chen ZK, Metcalfe SM.

Transplant Proc. 1999 Feb-Mar;31(1-2):802-3. No abstract available.

PMID:
10083346
28.

In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin.

Metcalfe SM, Cockman M, Milner AJ.

Transplant Proc. 1998 Dec;30(8):4108-9. No abstract available.

PMID:
9865315
29.

Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells.

Metcalfe SM, Canman CE, Milner J, Morris RE, Goldman S, Kastan MB.

Oncogene. 1997 Oct 2;15(14):1635-42.

30.

Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody.

Smith RM, Chen ZK, Foulkes R, Metcalfe SM, Wraith DC.

Transplantation. 1997 Aug 15;64(3):525-8.

PMID:
9275122
31.

CD4 and CD8 monoclonal antibody therapy in the dog: strategies to induce tolerance to renal allografts.

Watson CJ, Davies HF, Cobbold SP, Rasmussen A, Rebello PR, Thiru S, Waldmann H, Calne RY, Metcalfe SM.

Transplant Proc. 1995 Feb;27(1):123-4. No abstract available.

PMID:
7878859
32.

Peptidylproline cis/trans isomerases.

Galat A, Metcalfe SM.

Prog Biophys Mol Biol. 1995;63(1):67-118. Review. No abstract available.

PMID:
7538221
33.

Production, selection, and testing of monoclonal antibodies to canine leukocytes in the dog kidney allograft model.

Davies HS, Cobbold SP, Watson CJ, Metcalfe SM, Rebello PR, Thiru S, McNair R, Rasmussen A, Waldmann H, Calne RY.

Transplant Proc. 1994 Aug;26(4):1941-2. No abstract available.

PMID:
7915056
34.

Tolerance induction in concordant heart-xenografted mice by CD4 and CD8 monoclonal antibodies.

Chen Z, Cobbold SP, Waldmann H, Metcalfe SM.

Transplant Proc. 1994 Jun;26(3):1199-200. No abstract available.

PMID:
8029885
35.

Tolerance of porcine renal allografts induced by donor spleen cells and seven days' treatment with cyclosporine.

Calne RY, Watson CJ, Brons IG, Makisalo H, Metcalfe SM, Sriwatanawongsa V, Davies HS.

Transplantation. 1994 May 27;57(10):1433-5.

PMID:
8197602
36.

Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies.

Watson CJ, Cobbold SP, Davies HS, Rebello PR, Thiru S, McNair R, Rasmussen A, Waldmann H, Calne RY, Metcalfe SM.

Tissue Antigens. 1994 Mar;43(3):155-62.

PMID:
7916496
37.

CD4 and CD8 monoclonal antibody therapy in canine renal allografts.

Watson CJ, Cobbold SP, Davies HF, Rebello PR, Waldmann H, Calne RY, Metcalfe SM.

Transpl Int. 1994;7 Suppl 1:S322-4.

PMID:
11271241
38.

CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.

Watson CJ, Cobbold SP, Davies HS, Rebello PR, Waldmann H, Calne RY, Metcalfe SM.

Br J Surg. 1993 Nov;80(11):1389-92.

PMID:
8252344
39.

A comparative study of cyclosporine and its derivative SDZ IMM-125 in canine renal allografts.

Watson CJ, Metcalfe SM, St John Collier DG, Calne RY.

Transplantation. 1993 Nov;56(5):1248-50.

PMID:
8249131
40.

The platelet-activating factor antagonist WEB 2170. Its beneficial effect on dog renal allograft survival.

Watson CJ, Luddington R, St John Collier DG, Calne RY, Metcalfe SM.

Transplantation. 1993 Oct;56(4):1047-9. No abstract available.

PMID:
8212192
41.

CD4 monoclonal antibodies in the preclinical dog renal allograft model.

Watson CJ, Davies HS, Metcalfe SM, Cobbold SP, Rebello PR, Collier DS, Waldmann H, Calne RY.

Transplant Proc. 1993 Feb;25(1 Pt 1):804-6. No abstract available.

PMID:
8438491
42.

Survival of renal allografted dogs after limited therapy with cyclosporine and the PAF antagonist WEB 2170.

Metcalfe SM, Watson CJ, Collier DG, DaCosta M, Friend PJ, Pollard SG, Luddington R, Calne RY.

Transplant Proc. 1991 Aug;23(4):2219-20. No abstract available.

PMID:
1871852
43.

Hyaluronic acid in the assessment of liver graft function.

Pollard SG, Forbes MA, Metcalfe SM, Cooper EH, Calne RY.

Transplant Proc. 1990 Oct;22(5):2301-2. No abstract available.

PMID:
2219379
44.

Tumour markers in breast cancer: a report on the extensive clinical use of B5 and CA15.3.

Metcalfe SM, Elyan SA, Wheeler TK.

Clin Oncol (R Coll Radiol). 1990 May;2(3):142-7.

PMID:
2261401
45.
46.

B5 tumour marker and urine cytology in diagnosis and follow-up of transitional cell bladder cancer.

Malpani K, Metcalfe SM, Hinchliffe A.

Br J Urol. 1989 Sep;64(3):257-62.

PMID:
2804562
47.

Cyclosporin-A binds lymphocyte surface receptors induced by activation.

Metcalfe SM, Watson JV, Kass T.

Immunol Lett. 1985;10(3-4):151-7.

PMID:
4044013
48.

A new tumour marker tested in 98 patients with bladder carcinoma.

Metcalfe SM, Jamieson NV.

Ann R Coll Surg Engl. 1984 Nov;66(6):399-401.

49.

The interaction of fluorescence and nuclear magnetic resonance probes with erythrocyte membrane protein fractions.

Randall RF, Stoddart RW, Metcalfe SM, Metcalfe JC.

Biochim Biophys Acta. 1972 Mar 17;255(3):888-99. No abstract available.

PMID:
5020229
50.

Cell culture as a test system for toxicity.

Metcalfe SM.

J Pharm Pharmacol. 1971 Nov;23(11):817-23. No abstract available.

PMID:
4400188

Supplemental Content

Loading ...
Support Center